Teva Defends IP Suit Over Generic MS Drug Research

Law360, New York (May 13, 2013, 7:20 PM EDT) -- Teva Pharmaceuticals Ltd. on Monday defended its patent suit over rival Sandoz Inc.’s attempt to develop a generic version of its multiple sclerosis drug Copaxone, saying legal safe harbors that protect generic development do not apply in this case.

Sandoz and partner Momenta Pharmaceuticals Inc. had no right to use a patented Teva compound in their Copaxone research, despite arguments that the practice is protected by a Hatch-Waxman Act patent infringement exemption for research, a Teva lawyer told U.S. District Judge Katherine Forrest at oral arguments...
To view the full article, register now.